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Contagious bovine pleuropneumonia (CBPP) is a severe infectious disease affecting ruminants of the Bos genus,
characterized by unilateral lesions of pleurisy and pneumonia. CBPP is caused by Mycoplasma mycoides subsp. mycoides
“Small Colony” (MmmSC) and it is transmitted by direct contact solely. Its distribution is not exactly known but recent reports
show that it is expanding in Africa and that it is threatening regions that have been CBPP-free for decades (Fig 1). Acutely
infected animals may be responsible for the rapid transmission of the disease while chronic carriers, with lesions known as
“sequestra”, may be responsible for the long term persistence of the disease in a region. Control strategies are based on
various measures such as slaughter, movement control, antibiotic treatment and vaccination. The vaccines that have been
used for decades in Africa were developed by Sheriff and Piercy and consist of a MmmSC strain that has been attenuated
empirically by in-vitro passages. These vaccines have a number of advantages and drawbacks (Table 1) and when used
alone they never allowed an eradication of the disease. One of the reasons is that African governments do not invest
sufficiently in animal disease control and that there is a lack of incentive for the investment in the development of new and
more efficient products as CBPP is not threatening developed countries.
For these reasons, it was decided to evaluate the potential of new types of products within the “VACNADA” project. These
products consisted in inactivated preparations of MmmSC antigen injected with adjuvants that could be compatible with the
development of multivalent vaccines. The objectives were to check if these vaccines elicited a noticeable sero-conversion
and, more importantly, if they were able to induce a protection.
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Recent introduction High risk of introduction
CBPP vaccines, strains T1/44 and T1sr
Advantages 
Quite cheap to produce
Very long conservation at -20°C once freeze-dried
Easy administration (sub-cutaneous)
T1sr: completely safe
Transient sero-conversion (allows detection of outbreaks)
Repeated vaccinations result in good protection
Drawbacks
Thermolability (freeze-dried or reconstituted)
Freeze-drying needs industrial skill
T1/44: has some residual virulence
Lack of sero-conversion does not allow sero-monitoring 
of vaccination campaigns
A single administration does not yield a good immunity
Protection is short-lived (T1sr: 6 months, T1/44: one year)
Eradication cannot be achieved with vaccination alone
CBPP is not a threat for developed countries
Antigen production: performed at CIRAD with strain MmmSC 8740, inactivation with BiEthylleneimine
Oil-adjuvant emulsionning: performed at SEPPIC, Castres, France
Administration: one dose subcutaneously (KARI), two doses intramuscularly (LCV)
Challenge: by the in-contact  with intubated animals procedure
Serology: by cELISA, IDEXX performed at LCV and KARI
In KARI, the animals that were immunized with a single dose
subcutaneously presented variable sero-conversions. A single animal
sero-converted while five of them had unexpected declining titer after the
seventh week.
No protection was evidenced in that group as compared to non-
vaccinated control groups
In LCV, the animals that were immunized twice intramuscularly presented
a remarkable sero-conversion with most animals reaching titers of 90
percent of inhibition at the time of challenge.
Complete protection was evidenced in that group.
Protection to CBPP is basically dependent on the cellular immune
response, hence the sero-conversion that was evidenced here is only a
marker of immune stimulation. Further work is needed to decipher which
components of the immune response lead to protection.
